SNX-5422 to Treat Solid Tumor Cancers and Lymphomas
NCT00644072
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
33
Enrollment
NIH
Sponsor class
Conditions
Lymphoma
Neoplasms
Interventions
DRUG:
SNX-5422
Sponsor
National Cancer Institute (NCI)